---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-088198"
form_type: "8-K"
ticker: null
cik: "0001708493"
company_name: "Harpoon Therapeutics, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T08:02:32.472560+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Harpoon Therapeutics receives two Nasdaq deficiency notices for bid price and equity

## Summary
- Bid price below $1.00 for 30 consecutive days; must comply by Sept 25, 2023.
- Stockholders' equity of $5.399M at Dec 31, 2022 fails Nasdaq's $10M minimum.
- Company has 45 days to submit a plan to regain equity compliance or consider transfer to Nasdaq Capital Market.
- For bid price, 180-day cure period with possible extension if other standards met and reverse split considered.
- Company intends to monitor and evaluate options including reverse stock split.

## SEC filing metadata
- accession: 0001193125-23-088198
- form_type: 8-K
- cik: 0001708493
- company_name: Harpoon Therapeutics, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708493/000119312523088198/0001193125-23-088198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708493/000119312523088198/d492534d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-088198
- JSON: https://secwatch.observer/filing/0001193125-23-088198.json
- Plain text: https://secwatch.observer/filing/0001193125-23-088198.txt

## Key facts
- Listing & Compliance Notices
  Harpoon Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: March 29, 2023, Harpoon Therapeutics, Inc., a Delaware corporation (the “Company”), received a notification letter (the “Bid Price Notice”) from the Listing Qualifications Staff (the “Nasdaq Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The Bid Price Notice has no immediate effect on the listing of the Company’s common stock on the Na
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708493/000119312523088198/0001193125-23-088198-index.htm
- Listing & Compliance Notices
  Harpoon Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5450(b)(1)(A)
  source text: March 30, 2023, the Company received a notification letter (the “Stockholders’ Equity Notice”) from the Nasdaq Staff indicating that the Company’s stockholders’ equity of $5,399,000, as reported in its Annual Report on Form 10-K for the year ended December 31, 2022, does not satisfy Nasdaq’s continued listing requirement set forth in Nasdaq Listing Rule 5450(b)(1)(A), which requires companies listed on the Nasdaq Global Select Market to maintain a minimum of $10,000,000 in stockholders’ equity. The Stockholders’ Equity Notice also has no immediate effect on the listing of the Company’s common
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708493/000119312523088198/0001193125-23-088198-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.